Valuation and Deal Structuring
M&A Mania –M&As by value up, 168% from 2013, even eclipsed the recent high in 2009. Allergan deal and commercial consolidation dominated. Biotech less than 10% of this volume. Number of Biotech Out-licensing Deals –Still running flat compared to recent years. Value of those Deals –Continued climb in valuations from already healthy levels.
Download Valuation and Deal Structuring
Information
Domain:
Source:
Link to this page:
Documents from same domain
Re: Medicare Prescription Drug Benefit Manual – …
www.bio.orginfusion therapy are in place before dispensing home infusion drugs.”2 This requires a home infusion pharmacy to provide the Part D plan with assurances that
Re: Medicare Prescription Drug Benefit Manual – …
www.bio.orgSeptember 26, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare & Medicaid Services
Consumer Products Made with Industrial …
www.bio.orgToxic chemicals, such as aniline, used in a nine step chemical synthesis process (hazardous waste generated)
Emerging Therapeutic Company Investment and Deal Trends
www.bio.org• Venture Capital: 2015 was the best year on record for US venture capital, with just under $7 billion raised. Funding Funding of immuno-oncology and neurodegenerative disease companies helped drive …
Presentation Title Goes Here and Second Line Here
www.bio.orgTM11 CALYSTA Energy Biology provides a real opportunity to produce high-value chemicals from novel feedstocks Calysta is a first mover in bioconversion of methane, enabling preferred partners to dramatically reduce feedstock costs Best-in-class technology, experienced management team, solid financial backing, extensive intellectual property, proven
Valuation and Deal Structuring
www.bio.orgValuation and Deal Structuring BIO’s Advanced Business Development Course June 2015 Prepared for: Joe Dillon President Bringing money to medicine© ℠ DILLONCAPITAL S T R A T E G I E S
Emerging Clinical Therapeutic Company Development ... - BIO
www.bio.org2 | BIO Industry Analysis About BIO BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and
Clinical Development Success Rates 2006-2015 - BIO
www.bio.orgAbout BIO BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
Clinical Development Success Rates 2006-2015
www.bio.orgthe most comprehensive analysis yet of biopharmaceutical R&D success. ... Only company-sponsored, FDA registration-enabling development programs were considered; investigator-sponsored studies ... This is also the point in development where industry must decide whether to pursue the large, expensive Phase III studies and may decide to terminate ...
Negotiation Strategies
www.bio.orge.g. Earlier stage assets requiring initial exploratory research phase More effort required in initial ‘finder’ phase, to identify partner with ideal strategic fit Candidate for ‘Reactive Review’ Approach to negotiation initially more general (one size fits all) …
Related documents
Health Care Sector Overview - Washington State University
s3.wp.wsu.eduAs for its valuation ratios, they are all significantly lower than the sector average. Although this can indicate a somewhat cheap stock, all the ratios are very much in line with the equipment industry average (Medtronic). With so many drug and equipment companies continuously creating products, there is need for a distribution industry.
The List
scdn.brownstoneresearch.comsignificant biotech acquisitions in history. These kinds of deals are very common with early stage biotech companies. And I always follow the management team when a great early stage company is acquired. Typically, the founders will stay on with the acquiring company for a defined period which is typically linked to their employment agreement.